Why Anacor Is Poised to Pull Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Anacor Pharmaceuticals has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Anacor and see what CAPS investors are saying about the stock right now.


Headquarters (founded)

Palo Alto, Calif. (2000)

Market Cap

$224.6 million



Trailing-12-Month Revenue

$10.7 million


CEO David Perry
CFO Geoffrey Parker

Return on Capital (average, past 3 years)



$45.5 million / $25.7 million


Johnson & Johnson

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 40% of the 43 members who have rated Anacor believe the stock will underperform the S&P 500 going forward.

Earlier this morning, one of those Fools, All-Star zzlangerhans, succinctly summed up the Anacor bear case for our community:

As predicted, in March the stock rebounded from the weak phase III performance of tavaborole with positive results from dose-ranging phase II trial of AN2728 in atopic dermatitis. But [$220M] is simply too much for a phase II drug in the crowded indication of atopic dermatitis. Anacor will certainly raise big before getting close to topline data from a phase III trial of AN2728, and approval of Valeant's efinaconazole in May will provide another nail for tavaborole's coffin.

While you can certainly make huge gains in biotechs, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Anacor Is Poised to Pull Back originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.